From: Prognostic value of systemic immune-inflammation index in patients with gastric cancer
Characteristic | SII < 660 [cases (%)] | SII ≥ 660 [cases (%)] | Χ 2 value | P value |
---|---|---|---|---|
Total | 283 | 161 | ||
Sex | 0.051 | 0.821 | ||
Men | 178 (62.9) | 103 (64.0) | ||
Women | 105 (37.1) | 58 (36.0) | ||
Age (years) | 9.250 | 0.002 | ||
<60 | 174 (61.5) | 75 (46.6) | ||
≥60 | 109 (38.5) | 86 (53.4) | ||
Tumor location | 5.667 | 0.059 | ||
Upper stomach | 82 (29.0) | 58 (36.0) | ||
Middle stomach | 83 (29.3) | 54 (33.5) | ||
Lower stomach | 118 (41.7) | 49 (30.4) | ||
Tumor size (cm) | 20.867 | <0.001 | ||
<5 | 164 (58.0) | 57 (35.4) | ||
≥5 | 119 (42.0) | 104 (64.6) | ||
Pathologic type | 4.642 | 0.326 | ||
Adenocarcinoma | 236 (83.4) | 131 (81.4) | ||
Squamous carcinoma | 12 (4.2) | 13 (8.1) | ||
Adenosquamous carcinoma | 3 (1.1) | 0 (0.0) | ||
Ring cell carcinoma | 26 (9.2) | 13 (8.1) | ||
Undifferentiated carcinoma | 6 (2.1) | 4 (2.5) | ||
Borrmann classification | 10.079 | 0.039 | ||
1 | 15 (5.3) | 15 (9.3) | ||
2 | 74 (26.1) | 24 (14.9) | ||
3 | 161 (56.9) | 98 (60.9) | ||
4 | 28 (9.9) | 22 (13.7) | ||
5 | 5 (1.8) | 2 (1.2) | ||
pT | 23.504 | <0.001 | ||
1 | 46 (16.3) | 7 (4.3) | ||
2 | 30 (10.6) | 11 (6.8) | ||
3 | 115 (40.6) | 60 (37.3) | ||
4 | 92 (32.5) | 83 (51.6) | ||
pN | 12.925 | 0.005 | ||
0 | 114 (40.3) | 38 (23.6) | ||
1 | 109 (38.5) | 76 (47.2) | ||
2 | 43 (15.2) | 34 (21.1) | ||
3 | 17 (6.0) | 13 (8.1) | ||
pM | 36.571 | <0.001 | ||
0 | 241 (85.2) | 96 (59.6) | ||
1 | 42 (14.8) | 65 (40.4) | ||
TNM stage | 40.848 | <0.001 | ||
I | 62 (21.9) | 15 (9.3) | ||
II | 47 (16.6) | 17 (10.6) | ||
III | 132 (46.6) | 64 (39.7) | ||
IV | 42 (14.8) | 65 (40.4) | ||
CEA (μg/L) | 4.778 | 0.029 | ||
<5 | 261 (92.2) | 138 (85.7) | ||
≥5 | 22 (7.8) | 23 (14.3) | ||
NLR | 52.974 | <0.001 | ||
<2.10 | 197 (69.6) | 8 (5.0) | ||
≥2.10 | 86 (30.4) | 153 (95.0) | ||
PLR | 86.897 | <0.001 | ||
<120 | 137 (48.4) | 7 (4.3) | ||
≥120 | 146 (51.6) | 154 (95.7) |